Moleculin Biotech, Inc. — Director's Dealing 2023

Dec 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2023-12-26

Reporting Person: Foster Jonathan P. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-26	Common Stock	P	28986	$0.69	Acquired	80556	Direct